Abstract: To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.
Abstract: The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R1, R2 and R2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R3 and R4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.
Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.
Type:
Grant
Filed:
August 23, 2013
Date of Patent:
December 13, 2016
Assignee:
APPLIED BIOSYSTEMS LLC
Inventors:
David Ruff, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
Abstract: An assembly, method, system, and apparatus for the assessment of the level of specific lipoprotein particles present in a bodily fluid are disclosed. The levels determined may be used to predict the risk of developing various diseases related to lipoprotein particles.
Type:
Grant
Filed:
September 8, 2010
Date of Patent:
November 8, 2016
Assignee:
Helena Laboratories Corporation
Inventors:
Philip Angelo Guadagno, Debra Linn Hicks, Joseph Paul McConnell
Abstract: The disclosure provides a method for assaying for a target analyte, comprising providing a plurality of samples which may comprise the target analyte, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry and determining from the mass spectrum the quantity of the target analyte in each sample.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
October 18, 2016
Assignee:
ELECTROPHORETICS LIMITED
Inventors:
Christian Baumann, Helen Byers, Peter Schulz-Knappe, Malcolm Ward
Abstract: The invention provides a compound of formula (I): (wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group); or (wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group).
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
September 13, 2016
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
September 6, 2016
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter FitzGerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
September 6, 2016
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
August 16, 2016
Assignee:
President and Fellows of Harvard College
Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.
Abstract: The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.
Abstract: Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging.
Type:
Grant
Filed:
October 5, 2012
Date of Patent:
April 19, 2016
Assignees:
BROWN UNIVERSITY, RHODE ISLAND HOSPITAL
Inventors:
Christoph Rose-Petruck, Jack R. Wands, Danielle Rand, Zoltan Derdak, Vivian Ortiz
Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.
Type:
Grant
Filed:
March 19, 2013
Date of Patent:
April 19, 2016
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Abstract: The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.
Abstract: It is an object of the present invention to provide an antibody that recognizes a canine TSH and binds thereto, without obtaining a large amount of canine TSH antigen. The present invention provides a monoclonal antibody produced by a hybridoma having Accession No. FERM BP-11490.
Abstract: Described herein are new recognition elements (antibodies or functional fragments thereof) that effectively bind to trinitrotoluene (TNT). Also disclosed is a single chain fragment recognition element.
Type:
Grant
Filed:
October 17, 2012
Date of Patent:
February 23, 2016
Assignee:
The United States of America, as represented by the Secretary of the Navy
Inventors:
Jinny Lin Liu, Daniel Zabetakis, Ellen R. Goldman, George P. Anderson
Abstract: A method includes providing a container, introducing a substance into the container, and introducing a readily dissolvable film into the container such that the dissolvable film overlies the substance within the container. An alternative method includes providing a container, providing a readily dissolvable film, the film comprising a substance carried by the film, and introducing the film into the container.
Abstract: The present invention presents designs for high extinction quenched “dyedrons” that can be activated by conversion of a single acceptor/quencher in the molecular assembly to a fluorescent state. The quencher is activated by noncovalent binding to a unique complementary expressible fluorogen activating peptide (FAP). In this way, the quencher serves as the homogeneous switch, receiving energy efficiently from each of the donor molecules of the dendronic antenna, and releasing it as fluorescence only when activated by binding. The sum of the extinction of the multiple dyes on the antenna will provide dramatic enhancements in the effective brightness of the probe in standard imaging systems. This approach provides a set of probes with exceptional brightness, specifically targeted to an expressed tag that activates the fluorescence of the dyedron.
Type:
Grant
Filed:
February 16, 2010
Date of Patent:
February 2, 2016
Assignee:
Carnegie Mellon University
Inventors:
Marcel P. Bruchez, Lauren A. Ernst, James Fitzpatrick, Chris Szent-Gyorgyi, Brigitte F. Schmidt, Alan Waggoner
Abstract: The invention provides compositions, kits, and methods for performing colorimetric analysis. A substrate is reacted to generate a chromogenic reaction product, and a reaction stop reagent that is a sulfonic acid is added to stop and stabilize the reaction product. The absorbance properties of the chromogenic reaction product can be maintained over significantly longer periods of time of that of conventional reagents and methods. The sulfonic acid can be used in assays such as ELISAs in order to provide a more accurate and safer detection of analytes in a biological sample.